1. Home
  2. AVIR vs NAUT Comparison

AVIR vs NAUT Comparison

Compare AVIR & NAUT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVIR
  • NAUT
  • Stock Information
  • Founded
  • AVIR 2012
  • NAUT 2016
  • Country
  • AVIR United States
  • NAUT United States
  • Employees
  • AVIR N/A
  • NAUT N/A
  • Industry
  • AVIR Medicinal Chemicals and Botanical Products
  • NAUT Biotechnology: Laboratory Analytical Instruments
  • Sector
  • AVIR Health Care
  • NAUT Industrials
  • Exchange
  • AVIR Nasdaq
  • NAUT Nasdaq
  • Market Cap
  • AVIR 276.9M
  • NAUT 284.7M
  • IPO Year
  • AVIR 2020
  • NAUT N/A
  • Fundamental
  • Price
  • AVIR $3.34
  • NAUT $2.49
  • Analyst Decision
  • AVIR Hold
  • NAUT Buy
  • Analyst Count
  • AVIR 1
  • NAUT 2
  • Target Price
  • AVIR $6.88
  • NAUT $4.50
  • AVG Volume (30 Days)
  • AVIR 155.8K
  • NAUT 113.6K
  • Earning Date
  • AVIR 11-07-2024
  • NAUT 10-29-2024
  • Dividend Yield
  • AVIR N/A
  • NAUT N/A
  • EPS Growth
  • AVIR N/A
  • NAUT N/A
  • EPS
  • AVIR N/A
  • NAUT N/A
  • Revenue
  • AVIR N/A
  • NAUT N/A
  • Revenue This Year
  • AVIR N/A
  • NAUT N/A
  • Revenue Next Year
  • AVIR N/A
  • NAUT N/A
  • P/E Ratio
  • AVIR N/A
  • NAUT N/A
  • Revenue Growth
  • AVIR N/A
  • NAUT N/A
  • 52 Week Low
  • AVIR $2.77
  • NAUT $2.19
  • 52 Week High
  • AVIR $4.60
  • NAUT $3.46
  • Technical
  • Relative Strength Index (RSI)
  • AVIR 44.81
  • NAUT 42.29
  • Support Level
  • AVIR $3.42
  • NAUT $2.35
  • Resistance Level
  • AVIR $3.62
  • NAUT $2.92
  • Average True Range (ATR)
  • AVIR 0.14
  • NAUT 0.18
  • MACD
  • AVIR 0.00
  • NAUT -0.03
  • Stochastic Oscillator
  • AVIR 30.00
  • NAUT 24.65

About AVIR Atea Pharmaceuticals Inc.

Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).

About NAUT Nautilus Biotechnolgy Inc.

Nautilus Biotechnology Inc is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the human proteome. It has built a prototype of a single-molecule instrument, Proteomic Analysis System.

Share on Social Networks: